FCM
CRL icon

Fourpath Capital Management’s Charles River Laboratories CRL Stock Holding History

Fourpath Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-851
Closed -$168K – 352
2024
Q3 		$168K Buy
+851
New +$177K 0.03% 233
2024
Q2 		– Sell
-868
Closed -$235K – 136
2024
Q1 		$235K Sell
868
-8
-0.9% -$1.91K 0.16% 120
2023
Q4 		$207K Buy
+876
New +$172K 0.14% 123

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Fourpath Capital Management's CRL Position: Q4 2024 in Review

Fourpath Capital Management sold out of Charles River Laboratories (CRL) in Q4 2024, closing a stake of 851 shares — an estimated $168K sold.

Fourpath Capital Management first reported a position in CRL in Q4 2023 and held it in 3 quarters. The position peaked at $235K in Q1 2024. 637 funds tracked by Wall St. Rank hold CRL as of Q4 2024.

  • Fourpath Capital Management reported no remaining Charles River Laboratories position as of Q4 2024 after selling out during the quarter.
  • Fourpath Capital Management sold 851 Charles River Laboratories shares in Q4 2024, an estimated $168K.
  • Fourpath Capital Management first reported a position in Charles River Laboratories in Q4 2023 and held it in 3 quarters.
  • Fourpath Capital Management's Charles River Laboratories position peaked at $235K in Q1 2024.
  • 637 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2024.

Based on Fourpath Capital Management's 13F filing for Q4 2024, filed 24 Jan 2025.